Naling Zhu1, Ru Xu2, Weiping Tang1, Haiying Wang1, Zhengwei Wan1, Xuedong Wu3, Yongshui Fu2, Shixing Tang1, Shouyi Yu1. 1. Guangdong Provincial Key Laboratory of Tropical Disease Research/Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou 510515, China. 2. Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou 510000, China. 3. Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Abstract
OBJECTIVE: To investigate the prevalence of HPgV-2 in blood donors, transfusion recipients and hemophilia patients and its impact on blood safety. METHODS: Serum samples were collected from 1060 healthy blood donors, 1402 HCV-positive and 500 HBV- positive blood donors, 570 transfusion recipients and 248 hemophilia patients for screening anti-HPgV-2 antibodies, HPgV-2 RNA, anti-HCV and HBsAg/HBV-DNA using ELISA and RT-PCR. Phylogenetic analysis of near fulllength genome sequences and NS3 genes of pegiviruses and hepaciviruses were performed using MEGA software. RESULTS: Anti-HPgV-2 positivity and HPgV-2 RNA positivity were found in 1.21% (17/1402) and 0.36% (5/1402) of the blood donors infected with HCV (RNA+/Ab+), respectively, indicating a close correlation between HPgV-2 and HCV infection (χ2=13.78, P= 0.004). Anti-HPgV-2 antibody was hardly detected in the other populations. A nucleotide identity as high as 97.11% was found in the NS3 fragments among the 5 isolated HPgV-2 strains, which had a nucleotide identity of 96.53% with the reported strains isolated out of China. CONCLUSIONS: The prevalence of HPgV-2 infection is rather low in healthy blood donors and transfusion recipients. Coinfection with HCV is common in HPgV-2 infection, and no evidence has now been available to support HPgV-2 transmission via blood transfusion, indicating that HPgV-2 may not pose a threat to blood safety.
OBJECTIVE: To investigate the prevalence of HPgV-2 in blood donors, transfusion recipients and hemophiliapatients and its impact on blood safety. METHODS: Serum samples were collected from 1060 healthy blood donors, 1402 HCV-positive and 500 HBV- positive blood donors, 570 transfusion recipients and 248 hemophiliapatients for screening anti-HPgV-2 antibodies, HPgV-2 RNA, anti-HCV and HBsAg/HBV-DNA using ELISA and RT-PCR. Phylogenetic analysis of near fulllength genome sequences and NS3 genes of pegiviruses and hepaciviruses were performed using MEGA software. RESULTS: Anti-HPgV-2 positivity and HPgV-2 RNA positivity were found in 1.21% (17/1402) and 0.36% (5/1402) of the blood donors infected with HCV (RNA+/Ab+), respectively, indicating a close correlation between HPgV-2 and HCV infection (χ2=13.78, P= 0.004). Anti-HPgV-2 antibody was hardly detected in the other populations. A nucleotide identity as high as 97.11% was found in the NS3 fragments among the 5 isolated HPgV-2 strains, which had a nucleotide identity of 96.53% with the reported strains isolated out of China. CONCLUSIONS: The prevalence of HPgV-2 infection is rather low in healthy blood donors and transfusion recipients. Coinfection with HCV is common in HPgV-2 infection, and no evidence has now been available to support HPgV-2 transmission via blood transfusion, indicating that HPgV-2 may not pose a threat to blood safety.
Authors: Abraham J Kandathil; Florian P Breitwieser; Jaiprasath Sachithanandham; Matthew Robinson; Shruti H Mehta; Winston Timp; Steven L Salzberg; David L Thomas; Ashwin Balagopal Journal: Ann Intern Med Date: 2017-06-06 Impact factor: 25.391
Authors: Michael G Berg; Deanna Lee; Kelly Coller; Matthew Frankel; Andrew Aronsohn; Kevin Cheng; Kenn Forberg; Marilee Marcinkus; Samia N Naccache; George Dawson; Catherine Brennan; Donald M Jensen; John Hackett; Charles Y Chiu Journal: PLoS Pathog Date: 2015-12-11 Impact factor: 6.823